PUBLISHER: BCC Research | PRODUCT CODE: 1267447
PUBLISHER: BCC Research | PRODUCT CODE: 1267447
Emerging Tools for Alzheimer's Disease
Highlights:
The goal is to provide an analysis of the emerging tools for the early detection of Alzheimer’s disease (AD) and their growth potential and future opportunities in the market. Because currently available tools are invasive and very expensive, there is a significant unmet need for non-invasive, cost-effective and early-detection tools. The study’s main objective is to present a comprehensive analysis of the emerging tools, including those that are approved and those in development, and predict their impact on the market.
Report Scope:
The report provides an overview of AD, and the current diagnostic methods. The report explains the need for emerging tools for the early detection of the disease. Tools that have been approved are discussed, as well as tools in the development phase. The report does not include therapeutics approved or in the pipeline for AD.
The report covers the global market for emerging tools with a look at the regional markets of North America, Europe and Emerging Markets.
The report provides a detailed analysis of the current and future global market for emerging tools. Industry growth drivers, restraints and opportunities are also discussed. The report also provides a look at the competitive landscape, profiles of companies developing tools for the early detection of AD, and the impact of COVID-19 on the market.
Report Includes:
- An overview of the global market for emerging tools for the early detection of Alzheimer's disease
- Estimation of the market size and analyses of global market trends, with data from 2020 to 2022, estimates for 2023 with projections of compound annual growth rates (CAGRs) through 2028
- Highlights of the current and future market potential and quantification of market based on type and region
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Detailed analysis of the regulatory framework and policies and product pipeline of the industry
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
Table of Contents
Chapter 1 Market Outlook
- 1.1 Market Snapshot
Chapter 2 Executive Summary
Chapter 3 Market Overview and Technology Background
- 3.1 Overview
- 3.2 Pathogenesis
- 3.3 Causes and Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
Chapter 4 Emerging Tools and Technologies
Chapter 5 Market Dynamics
- 5.1 Factors Affecting the Market for Emerging Tools for AD
- 5.2 Market Drivers
- 5.2.1 Increasing Prevalence of Alzheimer's Disease
- 5.2.2 High Unmet Need
- 5.2.3 Need to Identify the Right Patients for Clinical Trials
- 5.2.4 Increasing Investments and Funding
- 5.3 Market Restraints
- 5.3.1 Technological Challenges
- 5.3.2 Ethical Challenges
- 5.3.3 Reimbursement Challenges
- 5.4 Opportunities
- 5.5 Impact of COVID-19
Chapter 6 Emerging Tools for Alzheimer's Disease
- 6.1 North America
- 6.2 Europe
- 6.3 Emerging Markets
Chapter 7 Competitive Landscape and Analysis of Market Opportunities
- 7.1 Strategic Initiatives
- 7.2 Competitive Analysis
Chapter 8 Company Profiles
- ALTPEP
- ARACLON BIOTECH
- C2N DIAGNOSTICS LLC
- COGNOPTIX
- DIADEM SPA
- F. HOFFMANN-LA ROCHE AG (ROCHE)
- FUJIREBIO DIAGNOSTICS
- QUANTERIX CORP.
- QUEST DIAGNOSTICS INC.
- SYSMEX CORP.
Chapter 9 Project Scope and Methodology
- 9.1 Study Goals and Objectives
- 9.2 Reasons for Doing the Study
- 9.3 Scope of Report
- 9.4 Information Sources
- 9.5 Methodology
- 9.6 Market Breakdown by Region
- 9.7 Analyst's Credentials
- 9.8 BCC Custom Research
- 9.9 Related BCC Research Reports
List of Tables
- Summary Table : Global Market for Emerging Tools for Alzheimer's Disease, Through 2028
- Table 1 : Comparison of Diagnostic Biomarkers
- Table 2 : Peripheral Biomarkers in Development
- Table 3 : Digital Biomarkers in Development
- Table 4 : Examples of Blood-Based Biomarkers Used in Clinical Trials
- Table 5 : NIH Funding Estimates for Alzheimer's Disease Research
- Table 6 : Global Market for Emerging Tools for Alzheimer's Disease, by Region, Through 2028
- Table 7 : Strategic Initiatives for Companies Developing Tools for Alzheimer's Disease, 2019-March 2023
List of Figures
- Summary Figure : Global Market for Emerging Tools for Alzheimer's Disease, 2020-2028
- Figure 1 : Stages in the Alzheimer's Disease Continuum
- Figure 2 : Differences between Normal and AD Brain Structure
- Figure 3 : Biomarker Targets by Test Type
- Figure 4 : Next-Generation Clinical Care Pathway
- Figure 5 : Clinical Development Success Rates for Alzheimer's Disease Drugs, 2008-2019
- Figure 6 : Potential Use of Blood-Based Biomarkers in Clinical Trials
- Figure 7 : DxA Funding for Biomarkers
- Figure 8 : Potential Use of Blood-Based Biomarkers in Primary Care
- Figure 9 : Global Market for Emerging Tools for Alzheimer's Disease, by Region, 2020-2028
- Figure 10 : Global Market Shares of Emerging Tools for Alzheimer's Disease, by Region, 2022
